How to Treat Right Heart Failure. Tips for Clinicians in Everyday Practice.

Heart Fail Clin

Department of Translational Medical Sciences, Federico II University, Via S Pansini, 5 - Naples, 80131, Italy; Italian Clinical Outcome Research and Reporting Program (I-CORRP); Division of Internal Medicine and Metabolism and Rehabilitation, Federico II University of Naples, Via S. Pansini 5, Bld.1

Published: January 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In recent years, several observations reported that intolerance of physical exertion and other cardinal symptoms in heart failure (HF) are closely related to the functionality of the right ventricular (RV), regardless of left heart. It has been demonstrated that the RV dysfunction complicates the course, aggravates the quality of life, and increases the mortality of HF patients. The present review is aimed to report tips physicians about the current therapeutic management of right HF during acute stage and chronic phase, shedding light on the RV and its failure and providing physicians with essential information for everyday clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2022.08.022DOI Listing

Publication Analysis

Top Keywords

heart failure
8
treat heart
4
failure tips
4
tips clinicians
4
clinicians everyday
4
everyday practice
4
practice years
4
years observations
4
observations reported
4
reported intolerance
4

Similar Publications

Introduction/objective: Oral glucocorticoids (OGC) are conventionally used as first-line treatment for dermatomyositis (DM) and polymyositis (PM). This study evaluated clinical and economic outcomes associated with long-term (LT) OGC use in DM/PM.

Methods: Adults with ≥ 2 medical claims of DM/PM 30‒365 days apart from January 1, 2016, to December 31, 2022, and ≥ 1 diagnosis code of a physician specialty of interest were selected from the MarketScan Commercial and Medicare Supplemental databases.

View Article and Find Full Text PDF

Sodium-glucose Cotransporter 2 (SGLT-2) inhibitors are oral antidiabetic drugs that were developed for the treatment of patients with diabetes mellitus and are now also approved for treating chronic heart failure and chronic kidney disease. By inhibiting SGLT‑2 in the proximal renal tubule, urinary excretion of glucose is increased. Large randomized trials have demonstrated improved glycemic control, reduced cardiovascular events and lower mortality but also an increased risk of urogenital infections and dehydration.

View Article and Find Full Text PDF

Evaluation of pulmonary hypertension in heart failure with preserved ejection fraction.

Heart Fail Rev

September 2025

Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA.

In contemporary clinical practice, pulmonary hypertension (PH) is most commonly caused by heart failure with preserved ejection fraction (HFpEF). This high prevalence of HFpEF-related PH has contributed to complexity in diagnosis and evaluation of PH in the context of other diseases such as the presence of risk factors for group 1 PH. In this review, we discuss emerging concepts guiding the evaluation, pathobiology, and treatment of PH in patients with HFpEF or HFpEF-associated risk factors.

View Article and Find Full Text PDF

Neuromuscular diseases are often accompanied by various types of sleep-related breathing disorders, which can exacerbate the underlying condition and are associated with a poor prognosis. Early identification is essential, and interventions such as non-invasive ventilation, oxygen therapy, and respiratory rehabilitation should be initiated promptly to mitigate disease progression and improve outcomes. Nevertheless, the rates of missed and misdiagnosed cases remain common in clinical practice.

View Article and Find Full Text PDF